➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Dow
McKinsey
AstraZeneca
Mallinckrodt
Harvard Business School
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Details for Patent: 10,076,555

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,076,555 protect, and when does it expire?

Patent 10,076,555 protects SCENESSE and is included in one NDA.

This patent has eleven patent family members in ten countries.

Summary for Patent: 10,076,555
Title:Methods of inducing melanogenesis in a subject
Abstract: Described herein are methods and compositions for inducing melanogenesis in a human subject. The method comprises administering to a subject an alpha-MSH analogue, in an effective amount and time to induce melanogenesis by the melanocytes in epidermal tissue of subject without inducing homologous desensitization of the melanocortin-1 receptors.
Inventor(s): Kleinig; Michael John (Brunswick, AU), Tice; Thomas R. (Indian Springs, AL), Staas; Jay K. (Marylene, AL)
Assignee: Clinuvel Pharmaceuticals Limited (Melbourne, AU)
Application Number:15/135,241
Patent Claim Types:
see list of patent claims
Use; Formulation; Delivery;

Drugs Protected by US Patent 10,076,555

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Clivunel Inc SCENESSE afamelanotide IMPLANT;SUBCUTANEOUS 210797-001 Oct 8, 2019 RX Yes Yes   Start Trial   Start Trial INCREASE PAIN-FREE LIGHT EXPOSURE IN ADULT PATIENTS WITH A HISTORY OF PHOTOTOXIC REACTIONS FROM ERYTHROPOIETIC PROTOPORPHYRIA (EPP)   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,076,555

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005269244   Start Trial
Canada 2575866   Start Trial
China 101076314   Start Trial
Denmark 1789076   Start Trial
European Patent Office 1789076   Start Trial
Spain 2566801   Start Trial
Japan 2008508324   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
McKinsey
Merck
Harvard Business School
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.